Related Experiment Video
Updated: Jun 9, 2026

08:56
Clinical Assessment of Spatiotemporal Gait Parameters in Patients and Older Adults
Published on: November 7, 2014
13.8K
A framework to standardize gait study protocols in Parkinson's disease.
Martina Mancini1, Jeffrey M Hausdorff2,3, Elisa Pelosin4,5
1Department of Neurology, Oregon Health & Science University, Portland, OR, USA.
Journal of Parkinson'S Disease
|February 26, 2025
Summary
Standardizing gait measures in Parkinson's disease (PD) research is crucial for consistent data. The GALOP committee recommends a minimum set of gait assessments to improve clinical trials and patient care.
Area of Science:
- Neurology
- Biomedical Engineering
- Clinical Trials
Background:
- Gait outcomes are highly sensitive for Parkinson's disease (PD) diagnosis, intervention effects, and progression monitoring.
- Lack of standardized protocols and gait measures hinders data aggregation and limits clinical trial adoption.
- Heterogeneity in results impedes the reliable use of gait analysis in research.
Purpose of the Study:
- To establish recommendations for a minimum set of gait measures for Parkinson's disease research.
- To enhance standardization across studies evaluating individuals with PD.
- To facilitate data aggregation and improve the consistency of gait outcome reporting.
Main Methods:
- The Gait Advisors Leading Outcomes for Parkinson's (GALOP) committee developed recommendations.
- A five-step approach informed by expert consensus on best practices was employed.
- Recommendations focus on standardizing protocols for quantitative gait measures.
Main Results:
- A minimum set of meta-data for gait protocols is recommended.
- A standardized minimum gait assessment protocol at a comfortable speed is proposed.
- Suggestions for challenging gait testing scenarios are included.
Conclusions:
- Standardized gait protocols and outcomes can accelerate PD research and clinical trials.
- Harmonizing protocols across sites will foster collaboration and improve data reliability.
- Open data sharing and standardized methods aim to enhance patient care and quality of life for individuals with PD.
Related Concept Videos
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

